Anavex Life Sciences
New York, New York, United States · Biotechnology, Health Care, Pharmaceutical
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzhe
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 42
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Public (AVXL)
- Website
- www.anavex.com
- Company page
Recent activity at Anavex Life Sciences
- : Anavex Life Sciences Appoints Dr. Terrie Kellmeyer as CEO and President
- : SEC 8-K (5.02): On November 1, 2026, Anavex Life Sciences Corp. appointed Terrie Kellmeyer, Ph.D. as the Chief Executive Officer and President of the Company, effective immediately. Dr. Kellmeyer, who has over 30 years of experience in the pharmaceutical industry, was serving as the Interim CEO since May 2026 prior to this appointment. Her annual base salary remains at $500,000 with an expected annual bonus of 30% of her base salary. Additionally, she was appointed to the Board of Directors on the same day, reducing the Board's size from six to five members, and the Company plans to search for an additional independent director to fill the vacant seat.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On October 20, 2026, Anavex Life Sciences Corp. provided an update in a press release regarding its clinical development of blarcamesine (ANAVEX ® 2-73). The announcement highlighted the successful completion of two pharmacology studies: an ADME (absorption, distribution, metabolism, and excretion) study and a DDI (drug-drug interaction) study. This development is significant as it represents a key milestone in the clinical trials for blarcamesine, which has potential therapeutic implications for treating neurodegenerative disorders. The press release is included as Exhibit 99.1 to the filing, underscoring the importance of this progress for stakeholders and investors.
- : SEC 8-K (8.01): On October 15, 2026, Anavex Life Sciences Corp. announced via a press release that it received notification from the U.S. Food and Drug Administration allowing it to proceed with its planned clinical study for blarcamesine aimed at treating Fragile X syndrome. This approval is a key milestone for the company, signaling progress in their research and potential future developments in treatment solutions for this condition. The notification signifies regulatory approval, which is crucial for the advancement of the clinical trial process. The press release outlining these details is filed as Exhibit 99.1 with the 8-K report.
- : SEC 8-K (5.01):
- : SEC 8-K (8.01): On September 9, 2026, Anavex Life Sciences Corp. announced that the U.S. Food and Drug Administration (FDA) has granted their request for a meeting to discuss the inclusion of pediatric patients in their Phase 3 clinical trial for ANAVEX 2-73, a treatment being developed for Rett syndrome. This marks a significant step in advancing their clinical development pipeline for early Alzheimer’s disease and other related conditions. The Company is prioritizing the clinical advancement for ANAVEX®2-73 in various diseases, which may have strategic implications for expanding the patient demographic in their ongoing trials.
- : SEC 8-K (8.01): On September 2, 2026, Anavex Life Sciences Corp. announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after timely filing its Quarterly Reports for the periods ended March 31, 2026, and June 30, 2026. This announcement follows a delinquency notification received by the Company on May 20, 2026, due to the failure to file the reports on time. The Company submitted a compliance plan to Nasdaq on July 20, 2026, which led to the confirmation of compliance announced today. This compliance is crucial for maintaining the Company’s listing on Nasdaq and may positively impact investor confidence and market perception.
- : SEC 8-K (7.01): On August 17, 2026, Anavex Life Sciences Corp. issued a Regulation FD Disclosure regarding the mailing of a Stockholder Letter related to its 2026 Annual Meeting of Stockholders. The announcement included a new website, www.voteanavex.com, which provides details about the upcoming Annual Meeting. The Press Release and Stockholder Letter are included as Exhibits 99.1 and 99.2, respectively. This communication is essential for informing stockholders and promoting their participation in the meeting, which is a critical aspect of corporate governance.
- : SEC 8-K (7.01): On August 11, 2026, Anavex Life Sciences Corp. issued a press release announcing the filing of its definitive proxy statement for the 2026 Annual Meeting of Stockholders. The press release includes an open letter to stockholders outlining plans to refresh the Board of Directors during the upcoming meeting, indicating significant potential changes in corporate governance. This update is part of the company's ongoing efforts to enhance board effectiveness and align with shareholder interests. The filing serves to inform investors about these important changes ahead of the meeting, emphasizing Anavex's commitment to governance and stakeholder engagement.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Terrie Kellmeyer, Ph.D., President
- Terrie Kellmeyer, Chief Executive Officer
- David Goldberger, Senior Vp Of Product Growth
Verified email and direct lines for Anavex Life Sciences’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Companies similar to Anavex Life Sciences
- Lisata Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Specialised Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Windward Bio · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- IDRx · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Anavex Life Sciences: questions and answers
What does Anavex Life Sciences do?
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzhe
Where is Anavex Life Sciences headquartered?
Anavex Life Sciences is headquartered in New York, New York, United States.
How many employees does Anavex Life Sciences have?
Anavex Life Sciences has about 42 employees.
Who leads Anavex Life Sciences?
Terrie Kellmeyer, Ph.D. is a President at Anavex Life Sciences.
What is the latest news on Anavex Life Sciences?
On Nov 3, 2026, Anavex Life Sciences Appoints Dr. Terrie Kellmeyer as CEO and President
Is Anavex Life Sciences a public company?
Yes. Anavex Life Sciences is publicly traded under the ticker AVXL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy